Pandome

Panome Bio delivers advanced multi-omics services, specializing in next-generation metabolomics, lipidomics, proteomics, transcriptomics, and exposomics. Leveraging untargeted mass spectrometry, it generates high-quality, interpretable data, aiding researchers in translating biological alterations into actionable hypotheses. This provides deep insights via comprehensive workflows and tailored analysis.

Edward Weinstein, CEO, and Dr. Gary J. Patti, Chief Scientific Officer, co-founded Panome Bio in St. Louis in 2022. Their collaboration stemmed from the belief that an integrated multi-omics data approach was crucial for accelerating biomedical discovery. Weinstein leads executive functions; Dr. Patti, a distinguished metabolomics expert, guides scientific direction.

Panome Bio serves life science researchers and organizations uncovering biological mechanisms and identifying biomarkers. The company offers an innovative platform for integrated multi-omics analysis, fostering deeper understanding of biological systems. Its vision is to advance precision medicine via enhanced capabilities and scientific breakthroughs.